25 XP   0   0   10

Abcellera Biologics Inc
Buy, Hold or Sell?

Let's analyse Abcellera together

PenkeI guess you are interested in Abcellera Biologics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Abcellera Biologics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Abcellera Biologics Inc

I send you an email if I find something interesting about Abcellera Biologics Inc.

Quick analysis of Abcellera (30 sec.)










What can you expect buying and holding a share of Abcellera? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$3.94
Expected worth in 1 year
$3.66
How sure are you?
52.9%

+ What do you gain per year?

Total Gains per Share
$-0.28
Return On Investment
-7.1%

For what price can you sell your share?

Current Price per Share
$3.91
Expected price per share
$3.87 - $4.7499
How sure are you?
50%

1. Valuation of Abcellera (5 min.)




Live pricePrice per Share (EOD)

$3.91

Intrinsic Value Per Share

$-3.11 - $-3.88

Total Value Per Share

$0.83 - $0.06

2. Growth of Abcellera (5 min.)




Is Abcellera growing?

Current yearPrevious yearGrowGrow %
How rich?$1.1b$1.2b-$41.3m-3.5%

How much money is Abcellera making?

Current yearPrevious yearGrowGrow %
Making money-$36.5m$39.6m-$76.2m-208.3%
Net Profit Margin-394.9%-18.5%--

How much money comes from the company's main activities?

3. Financial Health of Abcellera (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#50 / 1016

Most Revenue
#306 / 1016

Most Profit
#839 / 1016

Most Efficient
#719 / 1016

What can you expect buying and holding a share of Abcellera? (5 min.)

Welcome investor! Abcellera's management wants to use your money to grow the business. In return you get a share of Abcellera.

What can you expect buying and holding a share of Abcellera?

First you should know what it really means to hold a share of Abcellera. And how you can make/lose money.

Speculation

The Price per Share of Abcellera is $3.91. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Abcellera.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Abcellera, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.94. Based on the TTM, the Book Value Change Per Share is $-0.07 per quarter. Based on the YOY, the Book Value Change Per Share is $0.18 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Abcellera.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.16-4.1%-0.13-3.2%0.133.2%0.051.3%0.051.3%
Usd Book Value Change Per Share-0.10-2.7%-0.07-1.8%0.184.5%0.235.9%0.235.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.10-2.7%-0.07-1.8%0.184.5%0.235.9%0.235.9%
Usd Price Per Share5.71-6.08-10.11-11.49-11.49-
Price to Earnings Ratio-8.86--12.47--26.47--49.97--49.97-
Price-to-Total Gains Ratio-54.89--98.52-13.09--40.13--40.13-
Price to Book Ratio1.45-1.50-2.50-3.52-3.52-
Price-to-Total Gains Ratio-54.89--98.52-13.09--40.13--40.13-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.91
Number of shares255
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.070.23
Usd Total Gains Per Share-0.070.23
Gains per Quarter (255 shares)-17.6359.04
Gains per Year (255 shares)-70.51236.15
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-71-810236226
20-141-1520472462
30-212-2230708698
40-282-2940945934
50-353-365011811170
60-423-436014171406
70-494-507016531642
80-564-578018891878
90-635-649021252114
100-705-720023612350

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%4.08.00.033.3%6.011.00.035.3%6.011.00.035.3%6.011.00.035.3%
Book Value Change Per Share0.04.00.00.0%6.06.00.050.0%9.07.01.052.9%9.07.01.052.9%9.07.01.052.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.017.00.0%0.00.017.00.0%0.00.017.00.0%
Total Gains per Share0.04.00.00.0%6.06.00.050.0%9.07.01.052.9%9.07.01.052.9%9.07.01.052.9%

Fundamentals of Abcellera

About Abcellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets, as well as strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Fundamental data was last updated by Penke on 2024-04-10 23:19:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Abcellera Biologics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Abcellera earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Abcellera to the Biotechnology industry mean.
  • A Net Profit Margin of -513.7% means that $-5.14 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Abcellera Biologics Inc:

  • The MRQ is -513.7%. The company is making a huge loss. -2
  • The TTM is -394.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-513.7%TTM-394.9%-118.7%
TTM-394.9%YOY-18.5%-376.4%
TTM-394.9%5Y-115.2%-279.7%
5Y-115.2%10Y-115.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-513.7%-197.2%-316.5%
TTM-394.9%-210.4%-184.5%
YOY-18.5%-279.3%+260.8%
5Y-115.2%-436.8%+321.6%
10Y-115.2%-599.3%+484.1%
1.1.2. Return on Assets

Shows how efficient Abcellera is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Abcellera to the Biotechnology industry mean.
  • -3.2% Return on Assets means that Abcellera generated $-0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Abcellera Biologics Inc:

  • The MRQ is -3.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -2.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.2%TTM-2.4%-0.7%
TTM-2.4%YOY2.5%-4.9%
TTM-2.4%5Y0.6%-3.0%
5Y0.6%10Y0.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.2%-13.6%+10.4%
TTM-2.4%-12.9%+10.5%
YOY2.5%-11.9%+14.4%
5Y0.6%-14.2%+14.8%
10Y0.6%-16.2%+16.8%
1.1.3. Return on Equity

Shows how efficient Abcellera is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Abcellera to the Biotechnology industry mean.
  • -4.1% Return on Equity means Abcellera generated $-0.04 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Abcellera Biologics Inc:

  • The MRQ is -4.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -3.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-4.1%TTM-3.1%-1.0%
TTM-3.1%YOY3.3%-6.4%
TTM-3.1%5Y-0.5%-2.6%
5Y-0.5%10Y-0.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.1%-17.0%+12.9%
TTM-3.1%-16.1%+13.0%
YOY3.3%-15.4%+18.7%
5Y-0.5%-20.0%+19.5%
10Y-0.5%-21.1%+20.6%

1.2. Operating Efficiency of Abcellera Biologics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Abcellera is operating .

  • Measures how much profit Abcellera makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Abcellera to the Biotechnology industry mean.
  • An Operating Margin of -682.8% means the company generated $-6.83  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Abcellera Biologics Inc:

  • The MRQ is -682.8%. The company is operating very inefficient. -2
  • The TTM is -610.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-682.8%TTM-610.4%-72.4%
TTM-610.4%YOY-18.6%-591.9%
TTM-610.4%5Y-161.4%-449.0%
5Y-161.4%10Y-161.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-682.8%-286.1%-396.7%
TTM-610.4%-224.4%-386.0%
YOY-18.6%-288.4%+269.8%
5Y-161.4%-475.2%+313.8%
10Y-161.4%-624.7%+463.3%
1.2.2. Operating Ratio

Measures how efficient Abcellera is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 8.82 means that the operating costs are $8.82 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Abcellera Biologics Inc:

  • The MRQ is 8.821. The company is inefficient in keeping operating costs low. -1
  • The TTM is 8.893. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ8.821TTM8.893-0.072
TTM8.893YOY1.176+7.717
TTM8.8935Y3.027+5.866
5Y3.02710Y3.0270.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.8212.997+5.824
TTM8.8933.247+5.646
YOY1.1763.766-2.590
5Y3.0275.675-2.648
10Y3.0277.857-4.830

1.3. Liquidity of Abcellera Biologics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Abcellera is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 7.33 means the company has $7.33 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Abcellera Biologics Inc:

  • The MRQ is 7.327. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.499. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.327TTM8.499-1.172
TTM8.499YOY7.301+1.198
TTM8.4995Y8.224+0.274
5Y8.22410Y8.2240.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.3273.930+3.397
TTM8.4994.251+4.248
YOY7.3015.436+1.865
5Y8.2246.045+2.179
10Y8.2246.363+1.861
1.3.2. Quick Ratio

Measures if Abcellera is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Abcellera to the Biotechnology industry mean.
  • A Quick Ratio of 12.20 means the company can pay off $12.20 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Abcellera Biologics Inc:

  • The MRQ is 12.202. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 13.729. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ12.202TTM13.729-1.526
TTM13.729YOY9.685+4.043
TTM13.7295Y16.112-2.384
5Y16.11210Y16.1120.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.2023.629+8.573
TTM13.7294.065+9.664
YOY9.6855.397+4.288
5Y16.1125.993+10.119
10Y16.1126.277+9.835

1.4. Solvency of Abcellera Biologics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Abcellera assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Abcellera to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.23 means that Abcellera assets are financed with 22.6% credit (debt) and the remaining percentage (100% - 22.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Abcellera Biologics Inc:

  • The MRQ is 0.226. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.215. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.226TTM0.215+0.011
TTM0.215YOY0.219-0.004
TTM0.2155Y0.265-0.050
5Y0.26510Y0.2650.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2260.332-0.106
TTM0.2150.334-0.119
YOY0.2190.268-0.049
5Y0.2650.366-0.101
10Y0.2650.390-0.125
1.4.2. Debt to Equity Ratio

Measures if Abcellera is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Abcellera to the Biotechnology industry mean.
  • A Debt to Equity ratio of 29.1% means that company has $0.29 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Abcellera Biologics Inc:

  • The MRQ is 0.291. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.274. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.291TTM0.274+0.017
TTM0.274YOY0.281-0.007
TTM0.2745Y0.387-0.113
5Y0.38710Y0.3870.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2910.381-0.090
TTM0.2740.390-0.116
YOY0.2810.334-0.053
5Y0.3870.434-0.047
10Y0.3870.466-0.079

2. Market Valuation of Abcellera Biologics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Abcellera generates.

  • Above 15 is considered overpriced but always compare Abcellera to the Biotechnology industry mean.
  • A PE ratio of -8.86 means the investor is paying $-8.86 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Abcellera Biologics Inc:

  • The EOD is -6.070. Based on the earnings, the company is expensive. -2
  • The MRQ is -8.864. Based on the earnings, the company is expensive. -2
  • The TTM is -12.470. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.070MRQ-8.864+2.794
MRQ-8.864TTM-12.470+3.606
TTM-12.470YOY-26.465+13.995
TTM-12.4705Y-49.970+37.499
5Y-49.97010Y-49.9700.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.070-2.315-3.755
MRQ-8.864-2.560-6.304
TTM-12.470-2.664-9.806
YOY-26.465-4.122-22.343
5Y-49.970-6.258-43.712
10Y-49.970-6.108-43.862
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Abcellera Biologics Inc:

  • The EOD is -8.407. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -12.277. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -25.613. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.407MRQ-12.277+3.870
MRQ-12.277TTM-25.613+13.335
TTM-25.613YOY11.615-37.227
TTM-25.6135Y-848.925+823.312
5Y-848.92510Y-848.9250.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-8.407-3.067-5.340
MRQ-12.277-3.251-9.026
TTM-25.613-3.545-22.068
YOY11.615-5.595+17.210
5Y-848.925-8.315-840.610
10Y-848.925-8.708-840.217
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Abcellera is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.45 means the investor is paying $1.45 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Abcellera Biologics Inc:

  • The EOD is 0.993. Based on the equity, the company is cheap. +2
  • The MRQ is 1.451. Based on the equity, the company is underpriced. +1
  • The TTM is 1.500. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.993MRQ1.451-0.457
MRQ1.451TTM1.500-0.049
TTM1.500YOY2.497-0.998
TTM1.5005Y3.515-2.016
5Y3.51510Y3.5150.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.9931.905-0.912
MRQ1.4512.111-0.660
TTM1.5002.095-0.595
YOY2.4972.836-0.339
5Y3.5153.443+0.072
10Y3.5153.794-0.279
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Abcellera Biologics Inc.

3.1. Institutions holding Abcellera Biologics Inc

Institutions are holding 43.871% of the shares of Abcellera Biologics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Baillie Gifford & Co Limited.8.21250.108824044796-2159853-8.2423
2023-12-31Baker Bros Advisors LP7.82481.488522909753214643010.3376
2023-12-31ING Investment Management LLC3.62870.07251062418500
2023-12-31Capital World Investors2.85240.00858351293-69200-0.8218
2023-12-31Credit Suisse First Boston (CSFB)1.56370.0252457825052730.1153
2023-12-31Orbimed Advisors, LLC1.42790.4768418076800
2023-12-31ArrowMark Colorado Holdings, LLC (ArrowMark Partners)1.40210.2587410509500
2023-12-31BlackRock Inc1.3340.0006390571349626714.5556
2023-12-31Founders Fund VII Management, LLC1.288989.827377353000
2023-12-31Lazard Asset Management LLC1.16540.024734120052651728.4266
2023-12-31Federated Hermes Inc1.06480.04423117680-136673-4.1997
2023-12-31Casdin Capital, LLC0.80611.3228236012900
2023-12-31Fidelity International Ltd0.64070.0113187587218758720
2023-12-31Guardian Capital Advisors LP0.61021.112178641400
2023-12-31Prosight Management, LP0.58063.89711700000-746000-30.4988
2023-12-31Renaissance Technologies Corp0.49850.01291459503-232550-13.7437
2023-12-31Millennium Management LLC0.42870.00311255219-266060-17.4892
2023-12-31Goldman Sachs Group Inc0.41070.00061202482943186363.7488
2023-12-31Novo A/S0.38490.3974112691500
2023-12-31Two Sigma Investments LLC0.36520.0141069238-128234-10.7087
Total 36.490899.1067106838840+1993630+1.9%

3.2. Funds holding Abcellera Biologics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Allianz Global Artfcl Intlgc W EUR2.09690.39376139452-12331-0.2004
2023-12-31American Funds SMALLCAP World A1.87170.0435548000000
2024-02-29Baillie Gifford Positive Change1.83440.95115370852-332665-5.8326
2024-02-29Baillie Gifford Positive Change B Acc1.83430.95175370488-431188-7.4321
2024-02-29CS (Lux) Digital Health Equity SB USD1.5371.4591450000000
2023-09-25SMDS Global AI Equity Mother1.53370.52064490520-135005-2.9187
2024-02-29Baillie Gifford WW Pstv Chg B USD Acc1.16240.96413403284-144630-4.0765
2023-12-31American Funds IS® Asset Allocation 10.98070.0638287129300
2024-03-28iShares Biotechnology ETF0.52850.0919154741100
2023-12-31Lazard Global Small Cap Equity0.44151.077812926321147399.741
2024-02-29ACATIS Datini Valueflex Fonds A0.34160.5861100000000
2023-11-20Nissay Glb Digital Hlthcare Equity MF0.33272.889397400014970018.1609
2023-11-20Nissay Glbl Digital Hlthcare Eq MF0.33272.889397400014970018.1609
2024-02-29Baillie Gifford Global Discovery A Acc0.32730.6539958227-25241-2.5665
2023-12-31Lazard Digital Health0.32253.294944285528725.9313
2023-12-31Edinburgh Worldwide Ord0.31370.5219918480-1616-0.1756
2023-11-30Baillie Gifford International Alpha 20.28540.176183545500
2023-12-31Mediolanum BB Global Impact L0.18970.3337555383-177049-24.1728
2023-12-31BrighthouseII Baillie Gifford Intl Stk A0.18640.205954583000
2024-02-29BlackRock Global Equity Mkt Netrl Instl0.18140.2052531176222514.3722
Total 16.634518.272748702768-770463-1.6%

3.3. Insider Transactions

Insiders are holding 28.089% of the shares of Abcellera Biologics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-05-26Andrew BoothBUY145006.85
2023-05-26Holdings Ltd. ThermopylaeBUY1530006.52

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Abcellera Biologics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.104-0.069-34%0.177-159%0.232-145%0.232-145%
Book Value Per Share--3.9364.046-3%4.047-3%2.871+37%2.871+37%
Current Ratio--7.3278.499-14%7.301+0%8.224-11%8.224-11%
Debt To Asset Ratio--0.2260.215+5%0.219+3%0.265-15%0.265-15%
Debt To Equity Ratio--0.2910.274+6%0.281+4%0.387-25%0.387-25%
Dividend Per Share----0%-0%-0%-0%
Eps---0.161-0.125-22%0.125-229%0.050-425%0.050-425%
Free Cash Flow Per Share---0.116-0.104-11%0.179-165%0.055-312%0.055-312%
Free Cash Flow To Equity Per Share---0.103-0.095-8%0.178-158%0.183-157%0.183-157%
Gross Profit Margin--1.0661.102-3%1.105-4%1.119-5%1.119-5%
Intrinsic Value_10Y_max---3.877--------
Intrinsic Value_10Y_min---3.108--------
Intrinsic Value_1Y_max--0.203--------
Intrinsic Value_1Y_min--0.199--------
Intrinsic Value_3Y_max--0.158--------
Intrinsic Value_3Y_min--0.160--------
Intrinsic Value_5Y_max---0.429--------
Intrinsic Value_5Y_min---0.360--------
Market Cap1144777682.560-46%1671785311.3601779382702.240-6%3061100397.575-45%3507191235.771-52%3507191235.771-52%
Net Profit Margin---5.137-3.949-23%-0.185-96%-1.152-78%-1.152-78%
Operating Margin---6.828-6.104-11%-0.186-97%-1.614-76%-1.614-76%
Operating Ratio--8.8218.893-1%1.176+650%3.027+191%3.027+191%
Pb Ratio0.993-46%1.4511.500-3%2.497-42%3.515-59%3.515-59%
Pe Ratio-6.070+32%-8.864-12.470+41%-26.465+199%-49.970+464%-49.970+464%
Price Per Share3.910-46%5.7106.078-6%10.105-43%11.486-50%11.486-50%
Price To Free Cash Flow Ratio-8.407+32%-12.277-25.613+109%11.615-206%-848.925+6815%-848.925+6815%
Price To Total Gains Ratio-37.587+32%-54.890-98.516+79%13.088-519%-40.132-27%-40.132-27%
Quick Ratio--12.20213.729-11%9.685+26%16.112-24%16.112-24%
Return On Assets---0.032-0.024-23%0.025-228%0.006-615%0.006-615%
Return On Equity---0.041-0.031-24%0.033-225%-0.005-88%-0.005-88%
Total Gains Per Share---0.104-0.069-34%0.177-159%0.232-145%0.232-145%
Usd Book Value--1152318000.0001184605000.000-3%1225953000.000-6%859240491.118+34%859240491.118+34%
Usd Book Value Change Per Share---0.104-0.069-34%0.177-159%0.232-145%0.232-145%
Usd Book Value Per Share--3.9364.046-3%4.047-3%2.871+37%2.871+37%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.161-0.125-22%0.125-229%0.050-425%0.050-425%
Usd Free Cash Flow---34042000.000-30346000.000-11%51175000.000-167%16314183.294-309%16314183.294-309%
Usd Free Cash Flow Per Share---0.116-0.104-11%0.179-165%0.055-312%0.055-312%
Usd Free Cash Flow To Equity Per Share---0.103-0.095-8%0.178-158%0.183-157%0.183-157%
Usd Market Cap1144777682.560-46%1671785311.3601779382702.240-6%3061100397.575-45%3507191235.771-52%3507191235.771-52%
Usd Price Per Share3.910-46%5.7106.078-6%10.105-43%11.486-50%11.486-50%
Usd Profit---47150000.000-36599500.000-22%39629750.000-219%16638974.588-383%16638974.588-383%
Usd Revenue--9179000.0009506500.000-3%121356500.000-92%66766627.765-86%66766627.765-86%
Usd Total Gains Per Share---0.104-0.069-34%0.177-159%0.232-145%0.232-145%
 EOD+3 -5MRQTTM+4 -30YOY+5 -295Y+7 -2710Y+7 -27

4.2. Fundamental Score

Let's check the fundamental score of Abcellera Biologics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-6.070
Price to Book Ratio (EOD)Between0-10.993
Net Profit Margin (MRQ)Greater than0-5.137
Operating Margin (MRQ)Greater than0-6.828
Quick Ratio (MRQ)Greater than112.202
Current Ratio (MRQ)Greater than17.327
Debt to Asset Ratio (MRQ)Less than10.226
Debt to Equity Ratio (MRQ)Less than10.291
Return on Equity (MRQ)Greater than0.15-0.041
Return on Assets (MRQ)Greater than0.05-0.032
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Abcellera Biologics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.512
Ma 20Greater thanMa 504.377
Ma 50Greater thanMa 1004.730
Ma 100Greater thanMa 2004.999
OpenGreater thanClose3.950
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,488,094
Total Liabilities335,776
Total Stockholder Equity1,152,318
 As reported
Total Liabilities 335,776
Total Stockholder Equity+ 1,152,318
Total Assets = 1,488,094

Assets

Total Assets1,488,094
Total Current Assets871,985
Long-term Assets616,109
Total Current Assets
Cash And Cash Equivalents 133,320
Short-term Investments 627,265
Net Receivables 64,382
Inventory 1,107
Other Current Assets 20,911
Total Current Assets  (as reported)871,985
Total Current Assets  (calculated)846,985
+/- 25,000
Long-term Assets
Property Plant Equipment 287,696
Goodwill 47,806
Long Term Investments 65,938
Intangible Assets 120,425
Long-term Assets Other 94,244
Long-term Assets  (as reported)616,109
Long-term Assets  (calculated)616,109
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities119,013
Long-term Liabilities216,763
Total Stockholder Equity1,152,318
Total Current Liabilities
Short-term Debt 6,158
Accounts payable 25,509
Other Current Liabilities 61,276
Total Current Liabilities  (as reported)119,013
Total Current Liabilities  (calculated)92,943
+/- 26,070
Long-term Liabilities
Capital Lease Obligations 77,380
Long-term Liabilities Other 5,906
Long-term Liabilities  (as reported)216,763
Long-term Liabilities  (calculated)83,286
+/- 133,477
Total Stockholder Equity
Common Stock753,199
Retained Earnings 279,787
Accumulated Other Comprehensive Income -1,720
Other Stockholders Equity 121,052
Total Stockholder Equity (as reported)1,152,318
Total Stockholder Equity (calculated)1,152,318
+/-0
Other
Capital Stock753,199
Cash and Short Term Investments 760,585
Common Stock Shares Outstanding 290,046
Current Deferred Revenue26,070
Liabilities and Stockholders Equity 1,488,094
Net Debt -55,940
Net Invested Capital 1,152,318
Net Working Capital 752,972
Property Plant and Equipment Gross 318,304
Short Long Term Debt Total 77,380



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-31
> Total Assets 
23,488
0
192,211
142,385
1,005,536
1,128,523
1,151,856
1,172,732
1,318,569
1,592,289
1,593,784
1,552,409
1,540,907
1,497,919
1,537,166
1,512,190
1,488,094
1,488,0941,512,1901,537,1661,497,9191,540,9071,552,4091,593,7841,592,2891,318,5691,172,7321,151,8561,128,5231,005,536142,385192,211023,488
   > Total Current Assets 
12,640
128,701
813,325
114,000
813,325
907,982
864,002
803,747
929,800
1,174,378
1,143,955
1,045,669
1,025,491
940,653
930,735
919,518
871,985
871,985919,518930,735940,6531,025,4911,045,6691,143,9551,174,378929,800803,747864,002907,982813,325114,000813,325128,70112,640
       Cash And Cash Equivalents 
7,553
0
594,116
91,082
594,116
685,795
792,571
517,694
476,142
545,718
790,615
371,973
386,535
193,017
179,747
172,422
133,320
133,320172,422179,747193,017386,535371,973790,615545,718476,142517,694792,571685,795594,11691,082594,11607,553
       Short-term Investments 
594,116
0
19,247
594,116
0
32,187
42,705
235,785
246,835
240,335
231,652
496,233
499,950
603,478
615,947
613,418
627,265
627,265613,418615,947603,478499,950496,233231,652240,335246,835235,78542,70532,1870594,11619,2470594,116
       Net Receivables 
4,378
14,522
903
20,109
213,239
216,442
64,884
43,633
160,576
334,403
52,797
105,964
103,410
99,569
86,233
75,483
64,382
64,38275,48386,23399,569103,410105,96452,797334,403160,57643,63364,884216,442213,23920,10990314,5224,378
       Other Current Assets 
-593,406
0
199,059
2,809
5,970
5,745
6,547
5,303
21,247
28,922
43,891
46,499
34,064
124,155
89,363
96,232
20,911
20,91196,23289,363124,15534,06446,49943,89128,92221,2475,3036,5475,7455,9702,809199,0590-593,406
   > Long-term Assets 
10,848
0
-621,114
28,386
192,211
220,541
287,854
368,985
388,769
417,911
449,829
506,740
515,416
557,266
606,431
592,672
616,109
616,109592,672606,431557,266515,416506,740449,829417,911388,769368,985287,854220,541192,21128,386-621,114010,848
       Property Plant Equipment 
8,480
11,616
17,923
14,278
17,923
34,618
87,479
91,584
111,616
122,049
149,178
200,602
217,255
233,187
259,640
277,209
287,696
287,696277,209259,640233,187217,255200,602149,178122,049111,61691,58487,47934,61817,92314,27817,92311,6168,480
       Goodwill 
31,500
0
31,500
31,500
31,500
31,500
31,500
49,457
47,806
47,806
47,806
47,806
47,806
47,806
47,806
47,806
47,806
47,80647,80647,80647,80647,80647,80647,80647,80647,80649,45731,50031,50031,50031,50031,500031,500
       Long Term Investments 
0
0
0
0
19,247
32,187
42,705
47,507
50,313
58,882
65,824
66,718
72,522
57,583
58,792
62,887
65,938
65,93862,88758,79257,58372,52266,71865,82458,88250,31347,50742,70532,18719,2470000
       Intangible Assets 
115,153
0
115,153
115,153
115,153
112,688
110,223
148,821
148,392
145,785
143,179
142,548
131,502
128,845
126,747
124,076
120,425
120,425124,076126,747128,845131,502142,548143,179145,785148,392148,821110,223112,688115,153115,153115,1530115,153
       Long-term Assets Other 
585
0
-785,690
-151,792
8,388
9,548
15,947
31,616
23,234
43,389
43,842
49,066
41,031
89,845
113,446
80,694
94,244
94,24480,694113,44689,84541,03149,06643,84243,38923,23431,61615,9479,5488,388-151,792-785,6900585
> Total Liabilities 
13,236
0
71,538
53,147
175,028
171,399
184,177
219,335
292,836
384,782
380,928
302,237
307,630
289,419
342,339
329,415
335,776
335,776329,415342,339289,419307,630302,237380,928384,782292,836219,335184,177171,399175,02853,14771,538013,236
   > Total Current Liabilities 
7,895
18,269
103,490
20,104
103,490
88,395
69,758
49,549
120,676
213,418
221,140
106,052
118,320
89,591
118,905
110,239
119,013
119,013110,239118,90589,591118,320106,052221,140213,418120,67649,54969,75888,395103,49020,104103,49018,2697,895
       Short-term Debt 
2,886
0
0
320
190
1,533
2,220
2,800
3,652
3,920
4,023
4,517
5,583
5,868
5,953
5,572
6,158
6,1585,5725,9535,8685,5834,5174,0233,9203,6522,8002,2201,533190320002,886
       Short Long Term Debt 
2,467
0
0
320
190
0
0
0
0
0
0
0
0
0
0
0
0
000000000000190320002,467
       Accounts payable 
1,643
2,522
2,522
36,152
20,005
13,287
18,276
8,908
32,017
10,352
10,313
9,319
14,828
17,569
21,025
17,432
25,509
25,50917,43221,02517,56914,8289,31910,31310,35232,0178,90818,27613,28720,00536,1522,5222,5221,643
       Other Current Liabilities 
129
14,948
96,901
-23,284
76,706
62,269
38,694
27,724
77,471
184,906
196,411
79,116
70,012
47,762
76,864
63,374
61,276
61,27663,37476,86447,76270,01279,116196,411184,90677,47127,72438,69462,26976,706-23,28496,90114,948129
   > Long-term Liabilities 
5,341
0
-31,952
33,043
71,538
83,004
114,419
169,786
172,160
171,364
159,788
196,185
189,310
199,828
223,434
219,176
216,763
216,763219,176223,434199,828189,310196,185159,788171,364172,160169,786114,41983,00471,53833,043-31,95205,341
       Long term Debt 
1,363
0
0
1,939
2,198
0
0
0
0
0
0
0
0
0
0
0
0
0000000000002,1981,939001,363
       Capital Lease Obligations 
3,061
0
0
3,066
3,715
18,506
31,020
30,064
36,413
40,276
36,782
76,108
82,258
83,133
84,032
80,757
77,380
77,38080,75784,03283,13382,25876,10836,78240,27636,41330,06431,02018,5063,7153,066003,061
       Other Liabilities 
1,336
26,686
26,686
28,038
65,625
65,131
83,399
142,522
134,014
135,008
127,029
124,594
112,635
0
145,355
143,991
0
0143,991145,3550112,635124,594127,029135,008134,014142,52283,39965,13165,62528,03826,68626,6861,336
       Long-term Liabilities Other 
0
0
0
4,320
4,422
931
1,657
133,589
134,790
134,560
125,172
162,042
3,086
166,402
190,256
5,051
5,906
5,9065,051190,256166,4023,086162,042125,172134,560134,790133,5891,6579314,4224,320000
       Deferred Long Term Liability 
0
0
0
0
0
26,992
25,510
36,197
37,370
36,804
34,616
34,143
33,178
33,426
33,178
0
0
0033,17833,42633,17834,14334,61636,80437,37036,19725,51026,99200000
> Total Stockholder Equity
10,252
0
830,508
89,238
830,508
957,124
967,679
953,397
1,025,733
1,207,507
1,212,856
1,250,172
1,233,277
1,208,500
1,194,827
1,182,775
1,152,318
1,152,3181,182,7751,194,8271,208,5001,233,2771,250,1721,212,8561,207,5071,025,733953,397967,679957,124830,50889,238830,508010,252
   Common Stock
5,122
5,373
5,373
88,582
710,387
711,139
714,758
718,088
722,430
725,755
726,825
730,427
734,365
742,816
744,756
747,914
753,199
753,199747,914744,756742,816734,365730,427726,825725,755722,430718,088714,758711,139710,38788,5825,3735,3735,122
   Retained Earnings Total Equity
0
0
0
0
0
231,423
229,100
207,720
267,666
436,239
429,454
456,078
426,185
386,075
355,547
0
0
00355,547386,075426,185456,078429,454436,239267,666207,720229,100231,42300000
   Accumulated Other Comprehensive Income 
-3,157
0
0
0
0
0
2,152
644
280
787
576
-717
-1,391
-2,021
-1,899
-1,460
-1,720
-1,720-1,460-1,899-2,021-1,391-7175767872806442,15200000-3,157
   Capital Surplus 
0
0
0
0
0
14,562
21,669
26,945
35,357
44,726
56,001
64,384
74,118
81,630
96,423
0
0
0096,42381,63074,11864,38456,00144,72635,35726,94521,66914,56200000
   Treasury Stock00000000000000000
   Other Stockholders Equity 
5,457
0
830,508
3,453
5,919
14,562
21,669
26,945
35,357
44,726
56,001
64,384
74,118
81,630
96,423
109,384
121,052
121,052109,38496,42381,63074,11864,38456,00144,72635,35726,94521,66914,5625,9193,453830,50805,457



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue38,025
Cost of Revenue-30,894
Gross Profit7,1317,131
 
Operating Income (+$)
Gross Profit7,131
Operating Expense-261,077
Operating Income-237,207-253,946
 
Operating Expense (+$)
Research Development175,658
Selling General Administrative60,999
Selling And Marketing Expenses14,180
Operating Expense261,077250,837
 
Net Interest Income (+$)
Interest Income42,247
Interest Expense-0
Other Finance Cost-0
Net Interest Income42,247
 
Pretax Income (+$)
Operating Income-237,207
Net Interest Income42,247
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-174,029-243,983
EBIT - interestExpense = -223,052
-174,029
-146,398
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-223,052-174,029
Earnings Before Interest and Taxes (EBITDA)-192,158
 
After tax Income (+$)
Income Before Tax-174,029
Tax Provision--27,631
Net Income From Continuing Ops-146,398-146,398
Net Income-146,398
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses261,077
Total Other Income/Expenses Net6,776-42,247
 

Technical Analysis of Abcellera
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Abcellera. The general trend of Abcellera is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Abcellera's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Abcellera Biologics Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 4.248 < 4.27 < 4.7499.

The bearish price targets are: 3.89 > 3.87.

Tweet this
Abcellera Biologics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Abcellera Biologics Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Abcellera Biologics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Abcellera Biologics Inc. The current macd is -0.19512619.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Abcellera price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Abcellera. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Abcellera price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Abcellera Biologics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAbcellera Biologics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Abcellera Biologics Inc. The current adx is 20.55.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Abcellera shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Abcellera Biologics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Abcellera Biologics Inc. The current sar is 4.61471736.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Abcellera Biologics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Abcellera Biologics Inc. The current rsi is 31.51. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Abcellera Biologics Inc Daily Relative Strength Index (RSI) ChartAbcellera Biologics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Abcellera Biologics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Abcellera price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Abcellera Biologics Inc Daily Stochastic Oscillator ChartAbcellera Biologics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Abcellera Biologics Inc. The current cci is -208.56150862.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Abcellera Biologics Inc Daily Commodity Channel Index (CCI) ChartAbcellera Biologics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Abcellera Biologics Inc. The current cmo is -46.40178871.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Abcellera Biologics Inc Daily Chande Momentum Oscillator (CMO) ChartAbcellera Biologics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Abcellera Biologics Inc. The current willr is -92.30684691.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Abcellera Biologics Inc Daily Williams %R ChartAbcellera Biologics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Abcellera Biologics Inc.

Abcellera Biologics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Abcellera Biologics Inc. The current atr is 0.21297666.

Abcellera Biologics Inc Daily Average True Range (ATR) ChartAbcellera Biologics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Abcellera Biologics Inc. The current obv is 42,768,084.

Abcellera Biologics Inc Daily On-Balance Volume (OBV) ChartAbcellera Biologics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Abcellera Biologics Inc. The current mfi is 25.38.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Abcellera Biologics Inc Daily Money Flow Index (MFI) ChartAbcellera Biologics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Abcellera Biologics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-14ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-16BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Abcellera Biologics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Abcellera Biologics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.512
Ma 20Greater thanMa 504.377
Ma 50Greater thanMa 1004.730
Ma 100Greater thanMa 2004.999
OpenGreater thanClose3.950
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Abcellera with someone you think should read this too:
  • Are you bullish or bearish on Abcellera? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Abcellera? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Abcellera Biologics Inc

I send you an email if I find something interesting about Abcellera Biologics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Abcellera Biologics Inc.

Receive notifications about Abcellera Biologics Inc in your mailbox!